Chemistry:Bavdegalutamide

From HandWiki

Bavdegalutamide is an experimental proteolysis targeting chimera that functions as a androgen receptor degrader.[1] It is being developed to treat metastatic castration-resistant prostate cancer.[2][3][4]

References

  1. ↑ "Bavdegalutamide" (in en). PubChem. U.S. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/Bavdegalutamide. 
  2. ↑ "Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer." (in en). Journal of Clinical Oncology 40 (16_suppl). June 2022. doi:10.1200/JCO.2022.40.16_suppl.TPS5106. ISSN 0732-183X. https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS5106. 
  3. ↑ "Bavdegalutamide - Arvinas". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800054393. 
  4. ↑ "Targeting androgen receptor degradation with PROTACs from bench to bedside". Biomedicine & Pharmacotherapy 158. February 2023. doi:10.1016/j.biopha.2022.114112. PMID 36508999. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Bavdegalutamide&oldid=4175335"